Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth

Oncogene

Volumn 29, Issue 38, 2010, Pages 5286-5298

  Cantelmo, A R ^a   Cammarota, R ^a   Noonan, D M ^a,b   Focaccetti, C ^a   Comoglio, P M ^c   Prat, M ^d   Albini, A ^a  

^a IRCCS MULTIMEDICA   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

angiogenesis; Antennapedia; cancer; cell penetrating peptides; Met; Tat

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTENNAPEDIA PROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SYNTHETIC PEPTIDE; TRANSACTIVATOR PROTEIN; GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INTERNALIZATION; KAPOSI SARCOMA; MOLECULAR DOCKING; MORPHOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; AMINO ACID SEQUENCE; ANIMAL; APOPTOSIS; CELL LINE; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION; WESTERN BLOTTING; XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 77957119630     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.267     Document Type: Article

References (69)

1. Albini A, Benelli R. (2007). The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protocol 2: 504-511.
2. Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P et al. (1994). Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS 8: 1237-1244.
3. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM et al. (1987). A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47: 3239-3245.
4. Albini A, Morini M, D'Agostini F, Ferrari N, Campelli F, Arena G et al. (2001). Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res 61: 8171-8178.
5. Albini A, Paglieri I, Orengo G, Carlone S, Aluigi MG, DeMarchi R et al. (1997). The beta-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line. AIDS 11: 713-721.
6. Anastasi S, Giordano S, Sthandier O, Gambarotta G, Maione R, Comoglio P et al. (1997). A natural hepatocyte growth factor/scatter factor autocrine loop in myoblast cells and the effect of the constitutive Met kinase activation on myogenic differentiation. J Cell Biol 137: 1057-1068.
7. Bardelli A, Longati P, Williams TA, Benvenuti S, Comoglio PM. (1999). A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. J Biol Chem 274: 29274-29281.
8. Bardelli C, Sala M, Cavallazzi U, Prat M. (2005). Agonist Met antibodies define the signalling threshold required for a full mitogenic and invasive program of Kaposi's sarcoma cells. Biochem Biophys Res Commun 334: 1172-1179.
9. Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B et al. (2004). The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23: 5387-5393.
10. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. (2003). Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925.
11. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. (1995). Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376: 768-771.
12. Boccaccio C, Comoglio PM. (2006). Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6: 637-645.
13. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L et al. (1992). Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119: 629-641.
14. Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ et al. (2001). Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci USA 98: 7443-7448.
15. Cao R, Bjorndahl MA, Gallego MI, Chen S, Religa P, Hansen AJ et al. (2006). Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood 107: 3531-3536.
16. Carmeliet P, Jain RK. (2000). Angiogenesis in cancer and other diseases. Nature 407: 249-257.
17. Chan AM, Rubin JS, Bottaro DP, Hirschfield DW, Chedid M, Aaronson SA. (1991). Identification of a competitive HGF antagonist encoded by an alternative transcript. Science 254: 1382-1385.
18. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P et al. (2003). A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cyto-reductive antitumor activity in vivo. Cancer Res 63: 7345-7355.
19. Chu SH, Feng DF, Zhang H, Chen ET, Duan ZX, Li XY et al. (2009). c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro. J Neurooncol 93: 183-189.
20. Comoglio PM, Giordano S, Trusolino L. (2008). Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7: 504-516.
21. Corso S, Migliore C, Ghiso E, De Rosa G, Comoglio PM, Giordano S. (2008). Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene 27: 684-693.
22. Deregibus MC, Buttiglieri S, Russo S, Bussolati B, Camussi G. (2003). CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis. J Biol Chem 278: 18008-18014.
23. Deshayes S, Morris MC, Divita G, Heitz F. (2005). Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci 62: 1839-1849.
24. Di Renzo MF, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E et al. (1991). Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 6: 1997-2003.
25. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C. (2001). Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangio-genic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 61: 5911-5918.
26. Dong QG, Bernasconi S, Lostaglio S, De Calmanovici RW, Martin-Padura I, Breviario F et al. (1997). A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler Thromb Vasc Biol 17: 1599-1604.
27. Ebens A, Brose K, Leonardo ED, Hanson Jr MG, Bladt F, Birchmeier C et al. (1996). Hepatocyte growth factor/scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons. Neuron 17: 1157-1172.
28. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
29. Ferrara N. (2004). Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611.
30. Fischer C, Mazzone M, Jonckx B, Carmeliet P. (2008). FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8: 942-956.
31. Foged C, Nielsen HM. (2008). Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv 5: 105-117.
32. Folkman J. (1985). Tumor angiogenesis. Adv Cancer Res 43: 175-203.
33. Gherardi E, Sandin S, Petoukhov MV, Finch J, Youles ME, Ofverstedt LG et al. (2006). Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci USA 103: 4046-4051.
34. Giordano S, Maffe A, Williams TA, Artigiani S, Gual P, Bardelli A et al. (2000). Different point mutations in the met oncogene elicit distinct biological properties. FASEB J 14: 399-406.
35. Goh PP, Sze DM, Roufogalis BD. (2007). Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets 7: 743-758.
36. Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL et al. (1993). Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 90: 1937-1941.
37. Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, Kleinman HK. (1989). Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58: 933-943.
38. Graziani A, Gramaglia D, Cantley LC, Comoglio PM. (1991). The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem 266: 22087-22090.
39. Gupta B, Levchenko TS, Torchilin VP. (2005). Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 57: 637-651.
40. Jun HT, Sun J, Rex K, Radinsky R, Kendall R, Coxon A et al. (2007). AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87MG cells and xenografts. Clin Cancer Res 13: 6735-6742.
41. Khwaja A, Lehmann K, Marte BM, Downward J. (1998). Phospho-inositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway. J Biol Chem 273: 18793-18801.
42. Kim KJ, Wang L, Su YC, Gillespie GY, Salhotra A, Lal B et al. (2006). Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 12: 1292-1298.
43. Kleinman HK, McGarvey ML, Hassell JR, Star VL, Cannon FB, Laurie GW et al. (1986). Basement membrane complexes with biological activity. Biochemistry 25: 312-318.
44. Lock LS, Frigault MM, Saucier C, Park M. (2003). Grb2-independent recruitment of Gab1 requires the C-terminal lobe and structural integrity of the Met receptor kinase domain. J Biol Chem 278: 30083-30090.
45. Loges S, Mazzone M, Hohensinner P, Carmeliet P. (2009). Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15: 167-170.
46. Longati P, Bardelli A, Ponzetto C, Naldini L, Comoglio PM. (1994). Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene 9: 49-57.
47. Lou X, Zhou Q, Yin Y, Zhou C, Shen Y. (2009). Inhibition of the met receptor tyrosine kinase signaling enhances the chemosensitivity of glioma cell lines to CDDP through activation of p38 MAPK pathway. Mol Cancer Ther 8: 1126-1136.
48. Matsumoto K, Nakamura T. (2003). NK4 (HGF-antagonist/angio-genesis inhibitor) in cancer biology and therapeutics. Cancer Sci 94: 321-327.
49. Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L et al. (2004). An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest 114: 1418-1432.
50. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L et al. (2004). Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6: 61-73.
51. Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C. (2002). K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21: 4885-4893.
52. Morris MC, Deshayes S, Heitz F, Divita G. (2008). Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol Cell 100: 201-217.
53. Nishino T, Hisha H, Nishino N, Adachi M, Ikehara S. (1995). Hepatocyte growth factor as a hematopoietic regulator. Blood 85: 3093-3100.
54. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F et al. (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
55. Paranjpe S, Bowen WC, Bell AW, Nejak-Bowen K, Luo JH, Michalopoulos GK. (2007). Cell cycle effects resulting from inhibition of hepatocyte growth factor and its receptor c-Met in regenerating rat livers by RNA interference. Hepatology 45: 1471-1477.
56. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. (2003). Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361.
57. Ponzetto C, Bardelli A, Maina F, Longati P, Panayotou G, Dhand R et al. (1993). A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor. Mol Cell Biol 13: 4600-4608.
58. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S et al. (1994). A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77: 261-271.
59. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. (1998). Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 111(Part 2): 237-247.
60. Prat M, Narsimhan RP, Crepaldi T, Nicotra MR, Natali PG, Comoglio PM. (1991). The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer 49: 323-328.
61. Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M et al. (1995). Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373: 699-702.
62. Sengupta S, Gherardi E, Sellers LA, Wood JM, Sasisekharan R, Fan TP. (2003). Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 23: 69-75.
63. Silvagno F, Follenzi A, Arese M, Prat M, Giraudo E, Gaudino G et al. (1995). In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. Arter-ioscler Thromb Vasc Biol 15: 1857-1865.
64. Stewart KM, Horton KL, Kelley SO. (2008). Cell-penetrating peptides as delivery vehicles for biology and medicine. Org Biomol Chem 6: 2242-2255.
65. Uehara Y, Minowa O, Mori C, Shiota K, Kuno J, Noda T et al. (1995). Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373: 702-705.
66. Vigna E, Pacchiana G, Mazzone M, Chiriaco C, Fontani L, Basilico C et al. (2008). Active' cancer immunotherapy by anti-Met antibody gene transfer. Cancer Res 68: 9176-9183.
67. You WK, McDonald DM. (2008). The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 41: 833-839.
68. Zhang YW, Su Y, Volpert OV, Vande Woude GF. (2003). Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 100: 12718-12723.
69. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S et al. (2007). An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67: 4408-4417.